Strategic Inducement Grants by Protara Therapeutics
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company, is dedicated to developing groundbreaking treatments for cancer and rare diseases. Recently, the company revealed the issuance of inducement non-qualified stock options and restricted stock units (RSUs) to an employee newly hired to advance their mission.
Details of the Inducement Awards
The Compensation Committee from Protara’s Board of Directors sanctioned a total of 6,200 stock option grants and 3,100 RSUs specifically aimed at incentivizing the new hire. These inducements are noteworthy as they were structured in adherence to Nasdaq Listing Rule 5635(c)(4), ensuring compliance while fostering a supportive work environment for new team members.
Stock Options and Restricted Stock Units
These stock options were officially granted with an exercise price set at $4.41 per share, reflecting Protara's closing stock price from the grant date. The vesting schedule for the options is thoughtfully planned; the employee will see 25% of the shares become available after one year, followed by monthly vesting of the remaining shares over a 36-month term. On the other hand, the RSUs are designed to vest over a three-year period, granting one-third of the shares on each consecutive anniversary of the grant date. This arrangement is contingent upon the employee maintaining their role with Protara throughout these durations.
About Protara Therapeutics
Protara is focused on pioneering treatments that can have a lasting impact on patients wrestling with both cancer and rare diseases. One of their flagship products, TARA-002, represents their commitment to innovation, as it is an investigational cell-based therapy under development for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). Currently, Protara is conducting a Phase 2 clinical trial for TARA-002 targeting NMIBC patients who have not responded to traditional treatments with Bacillus Calmette-Guérin (BCG).
Investment in Pediatric Care
Protara's initiatives extend beyond adult cancers, as they are also investigating TARA-002 in a Phase 2 trial for pediatric patients dealing with lymphatic malformations. This reflects Protara’s dedication to addressing a diverse range of medical needs, further demonstrating their commitment to patient health and safety.
Innovations in Nutritional Therapy
In addition to their cancer therapies, Protara is advancing its development of IV Choline Chloride. This investigational product serves as a phospholipid substrate replacement for individuals relying on parenteral nutrition, ensuring they receive adequate choline which is essential for various bodily functions. This innovation is particularly crucial for patients unable to get enough choline through oral or enteral methods.
Company Contact Information
If you're interested in learning more about Protara Therapeutics or their innovative therapies, you can reach out to Justine O'Malley at Protara Therapeutics through the following contact:
Justine O'Malley
Protara Therapeutics
Email: Justine.OMalley@protaratx.com
Phone: 646-817-2836
Frequently Asked Questions
What is Protara Therapeutics focused on?
Protara Therapeutics is committed to developing transformative therapies for cancer and rare diseases.
What are the inducement grants mentioned?
The inducement grants involve stock options and RSUs awarded to new employees to incentivize their contribution to the company.
What is TARA-002?
TARA-002 is an investigational cell-based therapy for treating non-muscle invasive bladder cancer and lymphatic malformations.
How does Protara support pediatric patients?
Protara is conducting trials for TARA-002 aimed at treating pediatric patients with lymphatic malformations.
What therapeutic area does IV Choline Chloride address?
IV Choline Chloride is being developed for patients on parenteral nutrition who cannot meet their choline requirements through other dietary means.
